U.S. Electrical Stock News

NYSE:ELAN
NYSE:ELANPharmaceuticals

Elanco Screwworm Authorizations Spark Questions On Livestock Role And Valuation

Elanco Animal Health (NYSE:ELAN) has received emergency use authorizations from the U.S. FDA and EPA for Negasunt Powder and Tanidil to combat New World screwworm in livestock. The approvals give veterinarians and producers immediate tools to prevent and treat infestations as the parasite threat approaches the U.S. border. The authorizations were coordinated with federal and state agencies and focus squarely on protecting U.S. animal health during a potential outbreak. For investors...
NasdaqGS:FRMI
NasdaqGS:FRMISpecialized REITs

Is It Time To Reassess Fermi (FRMI) After The Sharp Year To Date Share Price Fall

If you are trying to figure out whether Fermi is attractively priced or not, the recent share performance gives you some very direct clues to work with. The stock last closed at US$5.13, with returns of a 13.3% decline over 7 days, a 12.2% decline over 30 days, and a 41.8% decline year to date, which will shape how you think about both potential upside and risk. Recent coverage has focused on how this pullback has put more attention on whether the current share price lines up with Fermi's...
NYSE:ECG
NYSE:ECGConstruction

Is It Too Late To Consider Everus Construction Group (ECG) After Its 244% One Year Surge?

If you are wondering whether Everus Construction Group is priced attractively or starting to look stretched, the recent share activity gives a useful starting point for a closer look at value. The stock closed at US$147.43, with returns of 8.1% over 7 days, 24.9% over 30 days, 65.3% year to date and 244.1% over 1 year, which puts valuation questions firmly on the table for any investor tracking the name. Recent coverage has focused on Everus Construction Group's strong share price...
NYSE:SW
NYSE:SWPackaging

Smurfit Westrock (SW) Margin Improvement Challenges Bearish Narrative In Q1 2026 Results

Smurfit Westrock (NYSE:SW) has just put fresh numbers on the table for Q1 2026, following a run where quarterly revenue has sat around US$7.5 billion to US$8.0 billion and EPS moved between US$0.19 and US$0.74 over the past year, alongside trailing 12 month earnings growth of 119.1%. Over recent quarters the company has seen revenue range from US$7.5 billion in Q4 2025 up to US$8.0 billion in Q3 2025, while basic EPS has swung from a loss of US$0.05 in Q2 2025 to US$0.74 in Q1 2025 and 1.34...
NYSE:CPT
NYSE:CPTResidential REITs

Is Camden Property Trust (CPT) Pricing Reflect Recent REIT Sentiment Shift?

Wondering if Camden Property Trust at around US$105 is offering value or asking too much? This article breaks down what the current price might actually reflect. The stock has a recent 7 day return of 2.5% and a 30 day return of 7.5%, yet sits on a year to date return of a 4.7% decline and a 1 year return of a 4.8% decline. This raises questions about how the market is reassessing risk and opportunity here. Recent coverage has focused on Camden Property Trust as a residential REIT, with...
NYSE:GRBK
NYSE:GRBKConsumer Durables

Green Brick Partners (GRBK) Margin Compression Reinforces Cautious Narratives Heading Into Q1 2026

Green Brick Partners (GRBK) has just opened Q1 2026 reporting season with a recent run of quarterly results that show total revenue between US$497.6 million and US$567.3 million and basic EPS ranging from US$1.67 to US$2.32 over the last six reported quarters, including net income between US$74.3 million and US$103.1 million. Over the past year, the company has seen trailing twelve month revenue around US$2.1 billion and basic EPS in a tight band between US$7.09 and US$8.51. This gives you a...
NasdaqGS:MGRC
NasdaqGS:MGRCTrade Distributors

McGrath RentCorp (MGRC) Margin Compression Challenges Bullish Rental Profitability Narratives

McGrath RentCorp (MGRC) opened 2026 with Q1 revenue of about US$198.5 million and basic EPS of roughly US$1.10, while trailing twelve month revenue stood at US$947.4 million with EPS of about US$6.30. The company reported quarterly revenue of US$195.4 million and EPS of roughly US$1.15 in Q1 2025, followed by a peak of US$256.8 million in revenue and EPS of about US$2.02 in Q4 2025 before this latest quarter. This progression provides context for how investors may assess margins as the new...
NYSE:RMD
NYSE:RMDMedical Equipment

ResMed Shifts Leadership And Adds Neurology With Noctrix Acquisition

ResMed (NYSE:RMD) appointed Aaron Bloomer as its new Chief Financial Officer, following the retirement announcement of long-serving CFO Brett Sandercock. The company also agreed to acquire Noctrix Health, a medical device firm focused on treatments for restless leg syndrome. Both announcements highlight changes in financial leadership and an expansion of ResMed’s portfolio beyond its core sleep apnea business. ResMed is best known for its sleep apnea devices and related software, a segment...
NYSE:TDOC
NYSE:TDOCHealthcare Services

Teladoc Health Q1 Loss Reduction Reinforces Bullish Margin Narrative Despite Flat Revenue

Teladoc Health (TDOC) opened 2026 with Q1 revenue of US$613.8 million and a basic EPS loss of US$0.36, alongside a trailing twelve month EPS loss of US$0.96 on revenue of US$2.5 billion. Over recent quarters, the company has seen revenue move from US$629.4 million in Q1 2025 to US$613.8 million in Q1 2026, while quarterly EPS shifted from a loss of US$0.53 to a loss of US$0.36 as net income moved from a loss of US$93.0 million to a loss of US$63.8 million. This keeps the focus firmly on how...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures

Class action lawsuit puts Oddity Tech (NasdaqGM:ODD) disclosures in focus A recent notice from The Gross Law Firm about a class action lawsuit against Oddity Tech (NasdaqGM:ODD) alleges misleading statements around digital advertising costs after an algorithm change by its largest advertising partner. See our latest analysis for Oddity Tech. The class action headlines arrive after a sharp reset in sentiment, with a 1 year total shareholder return of about 78% decline and a 90 day share price...